Univ. Grenoble Alpes, CNRS, DPM UMR 5063, F-38041, Grenoble, France; Univ. de Lyon 1, CNRS, MMSB UMR 5086, Drug Resistance & Membrane Proteins Lab, 69367, Lyon, France; Univ. Grenoble Alpes, CNRS, DCM UMR 5250, F-38041, Grenoble, France.
Univ. de Lyon 1, CNRS, MMSB UMR 5086, Drug Resistance & Membrane Proteins Lab, 69367, Lyon, France.
Eur J Med Chem. 2020 Sep 15;202:112503. doi: 10.1016/j.ejmech.2020.112503. Epub 2020 Jul 5.
The Breast Cancer Resistance Protein (BCRP/ABCG2) belongs to the G class of ABC (ATP-Binding Cassette) proteins, which is known as one of the main transporters involved in the multidrug resistance (MDR) phenotype that confer resistance to anticancer drugs. The aim of this study was to design, synthesize and develop new potent and selective inhibitors of BCRP that can be used to abolish MDR and potentialize clinically used anticancer agents. In previous reports, we showed the importance of chromone scaffold and hydrophobicity for the inhibition of ABC transporters. In the present study we report the design and development of chromones linked to one or two amino acids residues that are either hydrophobic or found in the structure of FTC, one of most potent (but highly toxic) inhibitors of BCRP. Herewith, we report the synthesis and evaluation of 13 compounds. The studied molecules were found to be not toxic and showed strong inhibition activity as well as high selectivity toward BCRP. The highest activity was obtained with the chromone bearing a valine residue (9c) which showed an inhibition activity against BCRP of 50 nM. The rationalization of the inhibition potential of the most active derivatives was performed through docking studies. Taken together, the ease of synthesis and the biological profile of these compounds render them as promising candidates for further development in the field of anticancer therapy.
乳腺癌耐药蛋白(BCRP/ABCG2)属于 ABC(ATP 结合盒)蛋白 G 类,是多药耐药(MDR)表型中涉及的主要转运蛋白之一,可赋予抗癌药物耐药性。本研究旨在设计、合成和开发新的强效和选择性 BCRP 抑制剂,可用于消除 MDR 并增强临床使用的抗癌药物的作用。在之前的报告中,我们展示了色酮骨架和疏水性对 ABC 转运蛋白抑制的重要性。在本研究中,我们报告了将色酮与一个或两个氨基酸残基连接的设计和开发,这些氨基酸残基要么是疏水性的,要么存在于 FTC(BCRP 的最强抑制剂之一)的结构中。在此,我们报告了 13 种化合物的合成和评价。研究的分子被发现没有毒性,并表现出强烈的抑制活性以及对 BCRP 的高选择性。带有缬氨酸残基的色酮(9c)表现出对 BCRP 的 50 nM 的抑制活性,具有最高的活性。通过对接研究对最活跃衍生物的抑制潜力进行了合理化。总之,这些化合物易于合成和良好的生物学特性使它们成为抗癌治疗领域进一步开发的有前途的候选药物。